Regular Article CLINICAL TRIALS AND OBSERVATIONS Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
نویسندگان
چکیده
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis Donna E. Reece, Ute Hegenbart, Vaishali Sanchorawala, Giampaolo Merlini, Giovanni Palladini, Joan Bladé, Jean-Paul Fermand, Hani Hassoun, Leonard Heffner, Vishal Kukreti, Robert A. Vescio, Lixia Pei, Christopher Enny, Dixie-Lee Esseltine, Helgi van de Velde, Andrew Cakana, and Raymond L. Comenzo
منابع مشابه
Brief Report CLINICAL TRIALS AND OBSERVATIONS A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
In amyloid light chain (AL) amyloidosis, clonal plasma cells use proteasomes to cope with misfolded light chain-induced proteotoxicity, and theproteasome inhibitor bortezomib is a potential targeted therapy. Early reports supported this expectation, showing high response rates, particularly upfront. A prospective trial showed that single-agent bortezomib ishighlyand rapidlyeffective.Combination...
متن کاملCLINICAL TRIALS AND OBSERVATIONS A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
In this phase 1/2 study, we explored the feasibility and activity of an oral regimen of lenalidomide with low-dose dexamethasone and low-dose oral cyclophosphamide (RdC) in patients with primary systemic light chain amyloidosis. RdC was given for up to 12 cycles in prespecified cohorts at escalated doses: 13 patients were treated in phase 1 and 24 in phase 2; 65% were previously untreated, and ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
1Princess Margaret Hospital, Toronto, ON; 2Amyloidosis Center, University of Heidelberg, Heidelberg, Germany; 3Boston University Medical Center, Boston, MA; 4Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Policlinico San Matteo, University of Pavia, Pavia, Italy; 5Hematology Department, Institute of Hematology and Oncology, Ins...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur S. Raje, Melissa Alsina, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura E. Lu...
متن کاملCLINICAL TRIALS AND OBSERVATIONS The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Given the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with relapsed indolent and mantle cell non-Hodgkin lymphoma, and laboratory studies suggesting synergistic activity, we conducted a multicenter phase 2 study of the bendamustine/ bortezomib/rituximab combination. Patients with relapsed or refractory indolent and mantle cell lymphoma with adequ...
متن کامل